Articles From: Aegion Corporation Appoints Charles R. Gordon President and Chief Executive Officer to Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference


2014/10/6
Aegion Corporation (“Aegion” or the “Company”) (Nasdaq Global Select Market: AEGN), a global leader in infrastructure protection and maintenance, today announced that its Board of Directors has appointed Charles R.
Sign-up for Aegion Corporation Appoints Charles R. Gordon President and Chief Executive Officer investment picks
2014/10/21
Aegion Corporation (Nasdaq Global Select Market: AEGN) will issue its financial results for the quarter ended September 30, 2014 on Wednesday, October 29, 2014 after market close.
Sign-up for Aegion Corporation to Announce Third Quarter 2014 Financial Results investment picks
KAUAI, Hawaii , Nov.
Sign-up for Aegis Combat System Goes Two For Two In Latest Flight Tests investment picks
2014/10/16
THE HAGUE, The Netherlands , October 16, 2014 /PRNewswire/ -- Aegon has reached an agreement with Wilton Re to sell its Canadian operations for CAD 600 million ( EUR 423 million ). The net underlying earnings of Aegon's Canadian operations were CAD 26 million over the trailing four quarters ending June 2014 , while its shareholders' equity excluding revaluation reserves on an IFRS basis amounted to CAD 1.8 billion at the end of June 2014 .
Sign-up for Aegon Announces Agreement to Sell its Canadian Life Insurance Business investment picks
2014/10/17
THE HAGUE, The Netherlands , October 17, 2014 /PRNewswire/ -- Aegon has completed the share buyback program announced on September 17, 2014 .
Sign-up for Aegon Completes Share Buyback Program investment picks
2014/9/17
THE HAGUE, the Netherlands , September 17, 2014 /PRNewswire/ -- Shareholders were given the opportunity to choose between receiving the interim dividend of EUR 0.11 per common share in cash or in stock.
Sign-up for Aegon Determines Stock Fraction Interim Dividend and Announces to Repurchase Shares to Neutralize Stock Dividend investment picks
2014/11/24
THE HAGUE, The Netherlands , November 24, 2014 /PRNewswire/ -- Aegon has reached an agreement to sell its 35% share in La Mondiale Participations to La Mondiale for EUR 350 million , in line with IFRS book value.
Sign-up for Aegon to Sell its Stake in La Mondiale Participations investment picks
2014/11/13
THE HAGUE, the Netherlands , November 13, 2014 /PRNewswire/ -- Outcome of annual assumptions review impacts underlying earnings Underlying earnings amount to EUR 291 million , impacted mainly by actuarial assumption changes Fair value items loss of EUR 296 million , due mostly to hedging programs and model updates Net income amounts to EUR 52 million Return on equity of 5.0%, or 8.5% excluding assumption changes and model updates Double-digit sales growth demonstrates strength of franchise Gross deposits up 38% to EUR 15.2 billion , driven by asset management and variable annuities; net deposits up 20% to EUR 3.5 billion Life sales increase 34% to EUR 552 million , as a result of strong production across markets Accident & health and general insurance sales 40% higher to EUR 257 million , driven by US Profitability of sales remains strong despite lower
Sign-up for Aegon's Earnings Impacted by Assumption Changes and Model Updates investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems Announces ABTS(TM) System Follow-On Order From Leading IC Manufacturer investment picks
FREMONT, Calif., Dec.
Sign-up for Aehr Test Systems Announces Changes to Its Board of Directors investment picks
FREMONT, Calif., Nov.
Sign-up for Aehr Test Systems Announces Private Placement of Common Stock investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems Reports First Quarter Fiscal 2015 Financial Results investment picks
FREMONT, Calif., Sept.
Sign-up for Aehr Test Systems to Announce First Quarter Fiscal 2015 Financial Results on September 30, 2014 investment picks
FREMONT, Calif., Dec.
Sign-up for Aehr Test Systems to Participate in the Third Annual Midtown CAP Investor Summit in New York investment picks
http://media.marketwire.com/attachments/201408/78116_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158405&ProfileId=051205&sourceType=1 CUPERTINO, CA --
Sign-up for Aemetis, Inc. Reports Third Quarter 2014 Results investment picks
COLUMBUS, Ohio , Nov.
Sign-up for AEP Honored As Adoption-Friendly Workplace For Eighth Time investment picks
COLUMBUS, Ohio , Oct.
Sign-up for AEP Increases Quarterly Dividend To 53 Cents A Share investment picks
Filing maintains grid reliability while protecting customers against price volatility GAHANNA, Ohio , Oct.
Sign-up for AEP Ohio Files Expanded Purchase Power Agreement investment picks
Company outlines 4 to 6 percent earnings growth strategy COLUMBUS, Ohio , Nov.
Sign-up for AEP Raises 2015 Operating Earnings Guidance, Reaffirms 2016 Operating Earnings Guidance Range investment picks
- Third-quarter 2014 GAAP and operating earnings $1.01 per share - Infrastructure investment continues to support earnings growth - 2014 operating earnings guidance range narrowed to $3.40 to $3.50 per share from $3.35 to $3.55 per share COLUMBUS, Ohio , Oct.
Sign-up for AEP Reports 2014 Third-Quarter Earnings; Narrows 2014 Operating Earnings Guidance Range investment picks
COLUMBUS, Ohio , Oct.
Sign-up for AEP Schedules Live Webcast Of Quarterly Earnings Call investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. (“Deerfield”), a current Aerie shareholder.
Sign-up for Aerie Announces Closing of $125 Million Convertible Notes Financing investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company’s 400-patient Phase 3 registration trial (“Rocket 1”) of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Sign-up for Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial (“Rocket 1”) of Rhopressa™, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma investment picks
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F.
Sign-up for Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for third quarter 2014 and provided an update on the Company’s business highlights.
Sign-up for Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014.
Sign-up for Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014 investment picks
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY.
Sign-up for Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Aegion Corporation Appoints Charles R. Gordon President and Chief Executive Officer to Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent